Home / Business and Economy / Cytokinetics CEO Blum Offloads 7,500 Shares Amidst Market Activity
Cytokinetics CEO Blum Offloads 7,500 Shares Amidst Market Activity
23 Aug
Summary
- CEO Robert I. Blum sold 7,500 Cytokinetics shares on August 10, 2026.
- The transaction involved exercising options and selling resulting shares.
- Despite the sale, Blum retains significant equity in Cytokinetics.
Robert I. Blum, the President and CEO of Cytokinetics (NASDAQ: CYTK), reported the sale of 7,500 shares on August 10, 2026. This transaction was executed by exercising stock options at a price of $10.60 per share, followed by an immediate sale of the resultant shares at a weighted-average price of $76.76.
Following this transaction, Blum maintains a significant equity position within Cytokinetics. His holdings include 377,820 direct shares and approximately 172,000 derivative securities, alongside 4,166 indirectly held shares. These indirect shares are split equally between two trusts: the Bridget Blum 2003 Irrevocable Trust and the Brittany Blum 2003 Irrevocable Trust.
As of the transaction date, Cytokinetics exhibited a market capitalization of $9.6 billion. The company's financial profile for the trailing twelve months showed revenue of $71.0 million against a net loss of -$894.0 million. This insider activity occurs within the context of the company's overall financial performance.
